<DOC>
	<DOCNO>NCT02850289</DOCNO>
	<brief_summary>This multi-center , observational study examine clinical use outcome pegylated interferon ( PEG-IFN ) alfa-2a ribavirin combination ( PEGASYS RBV ) participants chronic hepatitis C ( CHC ) . Study visit schedule baseline , 12 , 24 48 week baseline . An additional follow-up visit week 72 required participant HCV genotype 2 3 . Quality life data collect baseline , follow-up visit .</brief_summary>
	<brief_title>APPROACH Study : Quality Life Outcomes Assessment Participants With Chronic Hepatitis C ( CHC ) Treated With Pegylated Interferon ( PEG-IFN ) Alfa-2a Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Eligible schedule receive treatment commercially available PEGIFN alfa2a ribavirin combination Serologic evidence chronic hepatitis C ( CHC ) infection Detectable serum hepatitis C virus ribonucleic acid ( HCVRNA ) Negative urine blood pregnancy test Fertile participant receive treatment use two form effective contraception treatment 6 month treatment end Women ongoing pregnancy breast feeding , male partner woman pregnant Received investigational drug less equal ( &lt; /= ) 6 week prior enrollment Moderate hepatic failure [ ChildPugh great equal ( &gt; /= ) B ] Coinfection human immunodeficiency virus ( HIV ) hepatitis B Autoimmune hepatitis Known hypersensitivity alfa interferon , E. coliderived product , polyethylene glycol , ribavirin and/or ingredient formulation component PEGIFN alfa2a ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>